Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries

  • Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets
  • Rizmoic® is an innovative medicine for treating constipation caused by opioid pain relief medicines, in patients who have previously been treated with a laxative
  • Agreement reinforces Sandoz anti-pain franchise and commitment to pioneer access to healthcare in areas of unmet medical need

HOLZKIRCHEN, April 11 2019 – Sandoz today announces that it has …

/by

Sandoz resubmits biosimilar pegfilgrastim application to US FDA

  • Sandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim
     
  • Pegfilgrastim is used to reduce the incidence of neutropenia, one of the most serious side effects of chemotherapy, hospitalizing 60,000 US cancer patients each year1
     
  • Sandoz is committed to fostering biosimilar competition, to offer high-quality, cost-effective medicines and contribute to a more sustainable healthcare system

Holzkirchen, April 3, 2019 – …

/by

Novartis announces change in Sandoz leadership

  • Richard Francis, CEO Sandoz, to step down on March 31, 2019
  • Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz

Basel, March 14, 2019 – Novartis announced today that Richard Francis will be stepping down as CEO of Sandoz, a Novartis division, and as a member of the Executive Committee of Novartis on March 31, 2019. Francesco Balestrieri, currently Region Head Europe, Sandoz, has been appointed ad-interim CEO Sandoz. He will report to Vas Narasimhan, CEO, Novartis.

Vas Narasimhan said; “I would …

/by

Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW

  • Sandoz commits to increasing support from one winner to three, following impressive pitches from the finalists
  • Winning ideas proposed innovative uses of artificial intelligence, mobile apps and digital therapeutics to address healthcare access challenges
  • Sandoz invited people worldwide to “reimagine access to healthcare” by identifying practical, scalable digital solutions to address unmet medical needs

Austin, Texas, March 10, 2019 – Sandoz, a Novartis division, today announced the winners of the 2019 Sandoz …

/by

Sandoz certified Global Top Employer 2019

  • Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings globally
  • The Top Employers Institute is generally acknowledged as the global authority on recognizing excellence in people practices
  • This exclusive certification underlines our commitment to build a great place to work, based on a strong purpose-driven strategy

Holzkirchen, January 31, 2019 – Sandoz, a Novartis division, is honored to announce that it has been officially certified “Global Top Employer 2019” …

/by

Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018

  • Full year net sales up 5% (cc[1], +6% USD) driven by strong performance of growth drivers:
    • Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0 billion (+102% cc)
    • Oncology BU grew 9% (cc) driven by AAA[2] (USD 0.4 billion) including Lutathera, Promacta/Revolade USD 1.2 billion (+35% cc) and Tafinlar + Mekinist USD 1.2 billion (+31% cc)
  • Full year core[1] operating income grew 8% mainly driven by higher sales and gross margin expansion
  • Net income was USD …
/by

Sandoz selects three finalists for Healthcare Access Challenge (Sandoz HACk) from over 400 global entries

  • Competition generated ideas from more than 400 entrants in 80 countries – three shortlisted entrants from Uganda, the US and the Netherlands
  • Three finalists shared innovative uses of artificial intelligence, mobile apps and digital therapeutics to address local healthcare access challenges
  • Finalists will participate in a four-day “accelerator event” in March, collaborating with Sandoz to further refine their ideas, immediately ahead of final judging

Holzkirchen, January 16, 2019 – Sandoz, a Novartis division, …

/by

Sandoz Inc. launches SYMJEPI™ (epinephrine) in the US

Princeton, New Jersey, January 16, 2019 – Sandoz Inc. (Sandoz), a Novartis division, today announced the US market introduction of SYMJEPI™ (epinephrine) 0.3 mg Injection for the emergency treatment of allergic reactions (Type 1), including anaphylaxis. Sandoz is launching this medicine as an affordable, single-dose, pre-filled syringe alternative to epinephrine auto-injectors.

SYMJEPI will be rolled out through a phased launch, first in the institutional setting – an established channel where Sandoz Inc. has significant experience and knowledge – followed by introduction into …

/by

Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder

  • reSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder
  • Cleared by the FDA in December, reSET-O is available immediately
  • As part of a broader focus on digital healthcare solutions at Novartis, Sandoz aims to increase patient engagement and improve access to treatment through digital solutions

HOLZKIRCHEN, January 7, 2018 – Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O(TM) for patients with Opioid Use Disorder (OUD …

/by

Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises

  • Agreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart
  • Over 400 million people worldwide have diabetes and the amount of insulin required to treat type 2 diabetes alone is expected to increase by more than 20% from 2018 to 2030[1],[2]
  • Sandoz continues to strategically expand their biosimilars portfolio, with eight marketed biosimilars and a robust pipeline, showing ongoing commitment to accessible innovation

…

/by